Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From the EMPEROR-Preserved Trial
European Journal of Heart Failure 2023 DOI 10.1002/ejhf.2857
In the EMPEROR-Preserved trial, empagliflozin was found to improve the clinical outcomes of patients with heart failure and preserved ejection fraction (HFpEF). This pre-specified analysis sought to explore the effect of empagliflozin on cardiovascular (CV) and kidney outcomes across different levels of kidney function.
Participants were divided into two groups based on whether they had chronic kidney disease (CKD) at baseline. The primary outcome measured was a composite of CV death or first HF hospitalization.
The study included a total of 5988 patients who were randomized to either take empagliflozin or placebo. Out of these, 53.5% had CKD. Regardless of CKD status, those taking empagliflozin experienced a reduced risk in the primary outcome as well as key secondary outcomes regardless of CKD. Additionally, its effects on primary composite outcome and key secondary outcomes were consistent across five baseline eGFR categories, regardless of CKD status. Finally, empagliflozin was well tolerated.
